Generated: April 27, 2017
|Title:||Methods of treatment using single doses of oritavancin|
|Abstract:||Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.|
|Inventor(s):||Lehoux; Dario (Terrebonne, CA), Parr; Thomas R. (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA), Etienne; Pierre (Montreal, CA)|
|Assignee:||The Medicines Company (Parsippany, NJ)|
1. A method of treating a complicated skin and skin structure infection (cSSSI) in a subject, comprising administering a single dose of a therapeutically effective amount of a
pharmaceutical composition comprising oritavancin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent, over a course of therapy to a subject having cSSSI, wherein the single dose comprises at least 1200 mg
oritavancin, or a pharmaceutically acceptable salt thereof, thereby treating cSSSI in the subject.
2. The method of claim 1, wherein the single dose comprises between 1200 mg to 1800 mg oritavancin, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1, wherein said administering is via intravenous administration or oral administration.
4. The method of claim 1, wherein the bacteria causing cSSSI a is one or more bacteria selected from the group consisting of a gram-positive bacteria, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate Staphylococcus aureus, vancomycin hetero-intermediate Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus, Streptococcus dysgalactiae, Streptococcus dysgalactiae subsp. equisimilis, Enterococcus faecalis, vancomycin-resistant Enterococcus faecalis, Enterococcus faecium, and vancomycin-resistant Enterococcus faecium.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.